Empagliflozin also was associated with Improvement in quality of life and greater reduction in body weight.
July 2022
This inflammation of the colon poses a substantial burden to patients and the health care system.
Treatment's approval marks exciting new development for patients with ES-SCLC to prevent CIM.
Health system specialty pharmacies help remove barriers to care, optimize therapy, and improve outcomes.
Building a team to support best practices, medication safety, and staff education will reduce risks.
Patient education, naloxone training, and monitoring programs make a difference.
Surprising turn of events is a strong message to the pharmaceutical industry about the acceptable developmental pathway for this drug class.
The Pharmacy Times® Future of Pharmacy Resource Center is a comprehensive source on the evolution of the pharmacy profession and the growing roles of pharmacists
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
2
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
3
FDA Approves Targeted Combination Therapy for BRCA2-Mutated Prostate Cancer
4
Targeted ADCs Break Through Barriers in HER2-Positive Breast Cancer
5
